Novel Oxazolidinone Antibacterial Analogues with a Substituted Ligustrazine C-ring Unit

Chemical Biology and Drug Design

Volumn 86, Issue 4, 2015, Pages 682-690

  Chen, Yan ^a   Ruan, Zhi Xiong ^a   Wang, Fang ^a   Huangfu, De Sheng ^a   Sun, Ping Hua ^a   Lin, Jing ^a   Chen, Wei Min ^a  

^a JINAN UNIVERSITY   (China)

Author keywords

anti inflammatory; antibacterial; ligustrazine; linezolid; oxazolidinone

Indexed keywords

ANTIINFECTIVE AGENT; CHLOROACETAMIDE; INDOMETACIN; INTERLEUKIN 6; LINEZOLID; NITRIC OXIDE; OXAZOLIDINONE DERIVATIVE; TETRAMETHYLPYRAZINE; TUMOR NECROSIS FACTOR ALPHA; INTERLEUKIN-6, MOUSE; LIPOPOLYSACCHARIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PYRAZINE DERIVATIVE;

ANIMAL CELL; ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL VIABILITY; CHRONIC WOUND; CONTROLLED STUDY; CYTOTOXICITY; DRUG DESIGN; DRUG SYNTHESIS; IC50; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; CHEMISTRY; DRUG EFFECTS; GRAM POSITIVE BACTERIUM; MACROPHAGE; METABOLISM; MICROBIAL SENSITIVITY TEST; PRECLINICAL STUDY; PROCEDURES; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL LINE; CHEMISTRY TECHNIQUES, SYNTHETIC; DRUG EVALUATION, PRECLINICAL; GRAM-POSITIVE BACTERIA; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; MICROBIAL SENSITIVITY TESTS; NITRIC OXIDE; OXAZOLIDINONES; PYRAZINES; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84942502131     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12537     Document Type: Article

References (46)

1. Michalska K., Karpiuk I., Krõl M., Tyski S., (2013) Recent development of potent analogues of oxazolidinone antibacterial agents. Bioorg Med Chem; 21: 577-591.
2. Yang Y., You Q.D., (2010) Advances in the researches on SARs and structure modification of oxazolidinone antibacterial agents. Prog Pharm Sci; 34: 481-490.
3. Barbachyn M.R., Ford C.W., (2003) Oxazolidinone structure-activity relationships leading to linezolid. Angew Chem Int Ed; 42: 2010-2023.
4. Tsiodras S., Gold H.S., Sakoulas G., Eliopoulos G.M., Wennersten C., Venkataraman L., Moellering R.C., Ferraro M.J., (2001) Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet; 358: 207-208.
5. Toh S.M., Xiong L., Arias C.A., Villegas M.V., Lolans K., Quinn J., Mankin A.S., (2007) Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid. Mol Microbial; 64: 1506-1514.
6. Gonzales R.D., Schreckenberger P.C., Graham M.B., Kelkar S., DenBesten K., Quinn J.P., (2001) Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet; 357: 1179.
7. Brickner S.J., Hutchinson D.K., Barbachyn M.R., Manninen P.R., Ulanowicz D.A., Garmon S.A., Grega K.C., Hendges S.K., Toops D.S., Ford C.W., (1996) Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections. J Med Chem; 39: 673-679.
8. Das B., Rudra S., Yadav A., Ray A., Rao A., Srinivas A., Soni A., Saini S., Shukla S., Pandya M., (2005) Synthesis and SAR of novel oxazolidinones: discovery of ranbezolid. Bioorg Med Chem Lett; 15: 4261-4267.
9. Kalia V., Miglani R., Purnapatre K.P., Mathur T., Singhal S., Khan S., Voleti S.R., Upadhyay D.J., Saini K.S., Rattan A., (2009) Mode of action of ranbezolid against staphylococci and structural modeling studies of its interaction with ribosomes. Antimicrob Agents Chemother; 53: 1427-1433.
10. Skripkin E., McConnell T.S., DeVito J., Lawrence L., Ippolito J.A., Duffy E.M., Sutcliffe J., Franceschi F., (2008) Rχ-01, a new family of oxazolidinones that overcome ribosome-based linezolid resistance. Antimicrob Agents Chemother; 52: 3550-3557.
11. Medzhitov R., (2008) Origin and physiological roles of inflammation. Nature; 454: 428-435.
12. Gjødsbøl K., Christensen J.J., Karlsmark T., Jørgensen B., Klein B.M., Krogfelt K.A., (2006) Multiple bacterial species reside in chronic wounds: a longitudinal study. Int Wound J; 3: 225-231.
13. Thomas B., Klaus K.M., Peter Ø.J., Kit G.M., Richard P., Karen K., Niels H., Michael G., (2008) Why chronic wounds will not heal: a novel hypothesis. Wound Rep Reg; 16: 2-10.
14. Garth A.J., Ellen S., Randall W., Elinor D.P., Patrick S., Jennifer S., John W.C., Philip S.S., (2008) Biofilms in chronic wounds. Wound Rep Reg; 16: 37-44.
15. Medzhitov R., (2010) Inflammation 2010: new adventures of an old flame. Cell; 140: 771-776.
16. Corriveau C.C., Danner R.L., (1993) Endotoxin as a therapeutic target in septic shock. Infect Agents Dis; 2: 35-43.
17. Baumann H., Gauldie J., (1994) The acute phase response. Immunol Today; 15: 74-80.
18. Lawrence T., Willoughby D.A., Gilroy D.W., (2002) Anti-inflammatory lipid mediators and insights into the resolution of inflammation. Nat Rev Immunol; 2: 787-795.
19. Kubes P., Cafferty D.M., (2000) Nitric oxide and intestinal inflammation. Am J Med; 109: 150-158.
20. Park H.Y., Kim G.Y., Hyun J.W., Hwang H.J., Kim N.D., Kim B.W., Choi Y.H., (2012) 7,8-Dihydroxyflavone exhibits anti-inflammatory properties by downregulating the NF-κB and MAPK signaling pathways in lipopolysaccharide-treated RAW264.7 cells. Int J Mol Med; 29: 1146-1152.
21. MacMicking J., Xie Q.W., Nathan C., (1997) Nitric oxide and macrophage function. Annu Rev Immunol; 15: 323-350.
22. Cheng X.C., Liu X.Y., Xu W.F., Guo X.L., Ou Y., (2007) Design, synthesis, and biological activities of novel Ligustrazine derivatives. Bioorg Med Chem; 15: 3315-3320.
23. Ozaki Y., (1992) Anti-inflammatory effect of tetramethyl-pyrazine and ferulic acid. Chem Pharm Bull; 40: 954-956.
24. Hu J.Z., Huang J.H., Xiao Z.M., Li J.H., Li X.M., Lu H.B., (2013) Tetramethylpyrazine accelerates the function recovery of traumatic spinal cord in rat model by attenuating inflammation. J Neurol Sci; 324: 94-99.
25. Wu H.J., Hao J., Wang S.Q., Jin B.L., Chen X.B., (2012) Protective effects of ligustrazine on TNF-α-induced endothelial dysfunction. Eur J Pharmacol; 674: 365-369.
26. Kao T.K., Chang C.Y., Ou Y.C., Chen W.Y., Kuan Y.H., Pan H.C., Liao S.L., Li G.Z., Chen C.J., (2013) Tetramethylpyrazine reduces cellular inflammatory response following permanent focal cerebral ischemia in rats. Exp Neurol; 247: 188-201.
27. Gao Y., Xu C.S., Liang S.D., Zhang A., Mu S.N., Wang Y.X., Wan F., (2008) Effect of tetramethylpyrazine on primary afferent transmission mediated by P2X3 receptor in neuropathic pain states. Brain Res Bull; 77: 27-32.
28. Wu H.Y., Wei C.Y., Xu Q., Wang S.W., (2005) Anti-inflammatory and profibrinolytic effect of tetramethylpyrazine in acute coronary syndromes. J Geriatr Cardiol; 2: 233-235.
29. Wayne P.A., (2009) Performance standards for antimicrobial susceptibility testing; nineteenth informational supplement. CLSI document M100-S19; 29: 1-135.
30. Pandit N., Singla R.K., Shrivastava B., (2012) Current updates on oxazolidinone and its significance. Int J Med Chem; 2012: 1-24.
31. Hutchinson D.K., (2003) Oxazolidinone antibacterial agents: a critical review. Curr Top Med Chem; 3: 1021-1042.
32. Gravestock M.B., (2005) Recent developments in the discovery of novel oxazolidinone antibacterials. Curr Opin Drug Discov Devel; 8: 469-477.
33. Renslo A.R., Luehr G.W., Gordeev M.F., (2006) Synthesis and biological activities of new 1α,25-dihydroxy-19-norvitamin D3 analogs with modifications in both the A-ring and the side chain. Bioorg Med Chem; 14: 4227-4240.
34. Poce G., Zappia G., Porretta G.C., Botta B., Biava M., (2008) New oxazolidinone derivatives as antibacterial agents with improved activity. Informa Healthcare; 18: 97-121.
35. Gregory W.A., Brittelli D.R., Wang C., Wuonola M.A., Ripley R.J., Eustice D.C., Eberly V.S., Slee A.M., Forbes M., Bartholomew P., (1989) Antibacterials. Synthesis and structure-activity studies of 3-aryl-2-oxooxazolidines. 1. The B group. J Med Chem; 32: 1673-1681.
36. Renslo A.R., Luehr G.W., Lam S., Westlund N.E., Gõmez M., Hackbarth C.J., Patel D.V., Gordeev M.F., (2006) Synthesis and structure-activity studies of antibacterial oxazolidinones containing dihydrothiopyran or dihydrothiazine C-rings. Bioorg Med Chem Lett; 16: 3475-3478.
37. Gravestock M.B., Acton D.G., Betts M.J., Dennis M., Hatter G., Gregor A., Swain M.L., Wilson R.G., Woods L., Wookey A., (2003) New classes of antibacterial oxazolidinones with C-5, methylene O-Linked heterocyclic side chains. Bioorg Med Chem Lett; 13: 4179-4186.
38. Reck F., Zhou F., Girardot M., Kern G., Eyerman C.J., Hales N.J., Ramsay R.R., Gravestock M.B., (2005) Identification of 4-substituted 1,2,3-triazoles as novel oxazolidinone antibacterial agents with reduced activity against monoamine oxidase A. J Med Chem; 48: 499-506.
39. Hauck S.I., Cederberg C., Doucette A., Grosser L., Hales N.J., Poon G., Gravestock M.B., (2007) New carbon-linked azole oxazolidinones with improved potency and pharmacokinetics. Bioorg Med Chem Lett; 17: 337-340.
40. Ebnera D.C., Culhanea J.C., Winkelmana T.N., Hausteinb M.D., Ditty J.L., Ippoliti J.T., (2008) Synthesis of novel oxazolidinone antimicrobial agents. Bioorg Med Chem; 16: 2651-2656.
41. Ahmad S.S., Nevien A.S., (2009) Hydrazonoyl halides: their versatile biological activities. Open Bioact Compd J; 2: 8-16.
42. Im W.B., Choi S.H., Park J.Y., Choi S.H., Finn J., Yoon S.H., (2011) Discovery of torezolid as a novel 5-hydroxymethyl-oxazolidinone antibacterial agent. Eur J Med Chem; 46: 1027-1039.
43. Vallance P., (2003) Nitric oxide: therapeutic opportunities. Fund Clin Pharmacol; 17: 1-10.
44. Li X.Y., He J.L., Liu H.T., Li W.M., Yu C., (2009) Tetramethylpyrazine suppresses interleukin-8 expression in LPS-stimulated human umbilical vein endothelial cell by blocking ERK, p38 and nulear factor-κB signaling pathways. J Ethnopharmacol; 125: 83-89.
45. Yeom G.G.M., Min S., Kim S.Y., (2014) 2,3,5,6-Tetramethylpyrazine of Ephedra sinica regulates melanogenesis and inflammation in a UVA-induced melanoma/keratinocytes co-culture system. Int Immunopharmacol; 18: 262-269.
46. Dinarello C.A., (2000) Proinflammatory cytokines. Chest; 118: 503-508.